Shares of GSK PLC GSK advanced 1.58% to £13.49 Thursday, on what proved to be an all-around favorable trading session for the ...

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

GSK buys US-based rare cancer treatment developer for up to £1bn - The acquisition of IDRx will help GSK target a ‘major gap ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

GSK announced that it has agreed to terms to acquire IDRx, a clinical-stage biopharmaceutical company focused on developing precision ... along with a favorable safety profile. 1 “IDRX-42 complements ...

The investment seeks to provide investment results that correspond generally, before fees and expenses, to the total return of the ordinary shares of GSK plc in its local market. The series, under ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

London: GSK plc has announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, ...